Journals / İstanbul Medical Journal / 2013 / Cilt: 14 - Sayı: 3

Effect of Intravitreal Bevacizumab Injection on Iridocorneal Angle Width

İntravitreal Bevacizumab Enjeksiyonunun İridokorneal Açı Genişliğine Etkisi

Pages
188–190
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean SL-AOD before the injection was396.5±212.6 µ and mean SL-AOD after the injection was 364.3±215.4 µ.The difference was not statistically significant (p > 0.05).Conclusion: Intravitreal injection of 0,05 mL bevacizumab has no detectableeffect on anterior segment OCT images of iridocorneal angles in patientswho have Shaffer Grade 2 or wider angles.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the effect of intravitreal bevacizumab injection oniridocorneal angle width.Methods: Diabetic macular edema patients who l undergo intravitrealbevacizumab injection were included in the study if they had no iridocornealangle pathologies on gonioscopy.
📊
Key Findings & Data:Anterior segment optical coherencetomography was performed with RTVue (OptoVue Inc., Fremont, CA, USA)on 15 eyes of 15 patients to measure the angle opening distance at theSchwalbe’s line (SL-AOD) in the temporal quadrant before and just afterthe injection of 0.05 mL bevacizumab.
💡
Conclusion & Impact:Mean SL-AOD before the injection was396.5±212.6 µ and mean SL-AOD after the injection was 364.3±215.4 µ.The difference was not statistically significant (p > 0.05).Conclusion: Intravitreal injection of 0,05 mL bevacizumab has no detectableeffect on anterior segment OCT images of iridocorneal angles in patientswho have Shaffer Grade 2 or wider angles.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate the effect of intravitreal bevacizumab injection oniridocorneal angle width.Methods: Diabetic macular edema patients who l undergo intravitrealbevacizumab injection were included in the study if they had no iridocornealangle pathologies on gonioscopy. Anterior segment optical coherencetomography was performed with RTVue (OptoVue Inc., Fremont, CA, USA)on 15 eyes of 15 patients to measure the angle opening distance at theSchwalbe’s line (SL-AOD) in the temporal quadrant before and just afterthe injection of 0.05 mL bevacizumab. The effect of the intravitreal injectionon this parameter was evaluated.Results: 10 patients were male and 5 were female. The mean age was:58.4±5.5 years. All patients had Shaffer Grade 2 or wider angles in all thequadrants before the injection. Mean SL-AOD before the injection was396.5±212.6 µ and mean SL-AOD after the injection was 364.3±215.4 µ.The difference was not statistically significant (p > 0.05).Conclusion: Intravitreal injection of 0,05 mL bevacizumab has no detectableeffect on anterior segment OCT images of iridocorneal angles in patientswho have Shaffer Grade 2 or wider angles.

Özet

Amaç: İntravitreal bevacizumab enjeksiyonun iridokorneal açı genişliğine etkisinin incelenmesi. Yöntemler: Diyabetik makula ödemi nedeniyle intravitreal becavizumab enjeksiyonu planlanan ve gonyoskopisinde iridokorneal patoloji saptanmayan ardışık 15 hastanın 15 gözüne 0,05 mL bevacizumab enjeksiyondan hemen önce ve enjeksiyondan hemen sonra RTVue (OptoVue Inc., Fremont, CA, USA) cihazı ile temporal kadranı değerlendirecek şekilde ön segment optik koherens tomografisi (ÖS-OKT) çekilerek Schwalbe hattı hizasında açı açıklığı mesafesi (SH-AAM) ölçüldü ve enjeksiyonun bu parametre üzerine etkisi incelendi. Bulgular: Hastaların 10'u erkek 5'i kadın ve yaş ortalaması 58,4±5,5 idi. Hastaların tamamında enjeksiyon öncesi açı genişliği Shaffer sınıflamasına göre evre 2 ve üzerindeydi. Enjeksiyon öncesi ortalama SH-AAM 396,5±212,6 µ iken enjeksiyon sonrası ortalama SH-AAM 364,3±215,4 µ olarak saptandı. Aradaki fark istatistiksel olarak anlamlı değildi (p > 0,05). Sonuç: İridokorneal açıyı etkileyen bir patolojisi bulunmayan ve açı genişliği Shaffer sınıflamasına göre evre 2 ve üzerinde olan hastalarda 0,05 mL intravitreal enjeksiyonun iridokorneal açı genişliğine ÖS-OKT'si ile tespit edilebilir bir etkisi yoktur

🔖

Cite This Article

DOĞAN, M., AĞCA, A., ELTUTAR, K., ALTAN, T. (2022). Effect of Intravitreal Bevacizumab Injection on Iridocorneal Angle Width. İstanbul Medical Journal, Cilt: 14 - Sayı: 3, 188–190. https://ajindex.com/articles/552259

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Pavlin CJ, Harasiewicz K, Foster FS. Ultrasound biomicroscopy of anterior segment structures in normal and glaucomatous eyes. Am J Ophthalmol 1992; 113: 381-89
  2. Radhakrishnan S, Goldsmith J, Huang D, Westphal V, Dueker DK, Rollins AM, et al. Comparison of optical coherence tomography and ultrasound biomicroscopy for detection of narrow anterior chamber angles. Arch Ophthalmol 2005; 123: 1053-9.[CrossRef] 3. Ishikawa H, Liebmann JM, Ritch R. Quantitative assesement of the anterior segment using ultrasound biomicroscopy. Curr Opin Ophthalmol 2000; 11: 133-9. [CrossRef] 4. Cheung CY, Zheng C, Ho CL, Tun TA, Kumar RS, Sayyad FE, et al. Novel anterior chamber angle measurements by high definition optical coherence tomography using the Schwalbe line as the landmark. Br J Ophthalmol 2011; 95: 955-9. [CrossRef] 5. Fellman RL. Trabeculotomy. In: Spaeth GL ed. Ophthalmic surgery: principles and practice (3rd ed). Philadelphia; W. B. Saunders Company; 2003: 355-68
  3. Usui T, Tomidokoro A, Mishima K, Mataki N, Mayama C, Honda N, et al. Identification of Schlemm’s canal and its surrounding tissues by anterior segment Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci 2011; 52: 6934-9. [CrossRef] 7. Canut MI, Alvarez A, Nadal J, Abreu R, Abreu JA, Pulido JS. Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma. Clim Ophthalmol 2011; 5: 715-9. [CrossRef] 8. Semoun O, Blumen-Ohana E, de Preobrajensky N, Nordmann JP. Acute angle closure complicating an intravitreal injection of bevacizumab. J Fr Ophthalmol 2009; 32: 58.